Literature DB >> 3229859

Human monoclonal antibody against human lymphocytic cells. A human monoclonal antibody that reacts preferentially with human lymphocytic cells.

J Harpprecht1, M L Hansmann, E Westphal, W Müller-Ruchholtz.   

Abstract

Human monoclonal antibodies may replace human or xenogeneic antisera and mouse monoclonal antibodies for therapeutic applications. The human IgM monoclonal antibody Ha6D3 was produced after in vitro immunization and fusion with a mouse myeloma. Its reactivity against human normal and leukemic cells was investigated in cytotoxicity assays, and the antigen distribution in normal tissues was investigated with biotinylated Ha6D3 and avidin-peroxidase complexes. It was shown that Ha6D3 reacts preferentially with human lymphocytic cells. Only moderate reactions with epithelial cells in some organs were observed in cryostat sections, but because of poor accessibility in vivo these reactions were considered to be negligible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229859     DOI: 10.1159/000234709

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  2 in total

1.  HLA-antibody testing: the immune phagocytosis inhibition test is superior to the PRA-STAT and NIH lymphocytotoxic test with respect to specificity.

Authors:  B K Flesch; M Philipp; U Cassens; J Neppert
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Human monoclonal antibody Ha6D3, a candidate for treatment of leukaemia? In vitro reactivity of Ha6D3 with leukaemic cells and in vivo applications in a chimpanzee.

Authors:  J Harpprecht; M Jonker; H G Podzuweit; M L Hansmann; J Treumer; V Eckstein; P C van Eerd; W Müller-Ruchholtz
Journal:  Br J Cancer Suppl       Date:  1990-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.